Loading
Led OUTBACK, which showed adding chemotherapy after chemoradiation does not help cervical cancer, a key negative result.
Linda Mileshkin was principal investigator of OUTBACK, the ANZGOG-led international trial showing that adjuvant carboplatin-paclitaxel after chemoradiotherapy does not improve survival in locally advanced cervical cancer, sparing patients unnecessary toxicity. She also leads the CUPISCO and other trials in cancer of unknown primary and directs clinical trials at Peter Mac.
| Title | Journal | Year |
|---|---|---|
| Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK) | Lancet Oncology | 2023 |
| Cancer of unknown primary: challenges and progress in clinical management | Lancet Oncology | 2018 |
Shares Cervical cancer and the tags cervical, cooperative-group.
Shares Cervical cancer and the tags cervical, cooperative-group.
Shares OUTBACK / ANZGOG 0902 / GOG-0274, Cervical cancer and the tag cooperative-group.
Shares Peter MacCallum Cancer Centre and the tag cooperative-group.
Shares Peter MacCallum Cancer Centre and the tag cooperative-group.
Shares Peter MacCallum Cancer Centre and the tag australia.
Shares Peter MacCallum Cancer Centre and the tag cooperative-group.